ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT

European Urology Focus · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles